(CD19 þ , CyIgm þ ) ALL cases. However, in infant ALL patients (o1 year of age) the pro-B phenotype was not associated with sensitivity to Ara-C, but the number of infants with pre-B or common phenotypes was small.
The JAK-STAT pathway is a central mediator of cytokine signaling in hematopoietic cells, and its deregulation has been observed in human hematological and solid malignancies. The notion that JAK-STAT signaling may drive tumor formation has been strengthened by the identification of JAK2 genetic alterations in human leukemia. Initially, we and others have identified fusions of the JAK2 gene with the TEL(ETV6) gene in cases of human childhood T-cell acute lymphoblastic leukemia (ALL), pre-B ALL and atypical chronic myeloid leukemia (CML). 1, 2 More recently, JAK2 fusions with the PCM1 and BCR genes have also been identified in CML and pre-B ALL. 3, 4 In addition, a frequent JAK2 point mutation (JAK2 V617F ) has been identified in human clonal myeloproliferative disorders. 5 Both the TEL-JAK2 fusion and the JAK2 V617F mutation result in constitutive JAK2 tyrosine kinase activity. 
Letters to the Editor
Two different approaches have been pursued to model TEL-JAK2-induced leukemia in mice. Transgenic TEL-JAK2 expression driven by the EmSRa promoter/enhancer, which leads to B and T lymphoid-specific expression, resulted in highly penetrant oligoclonal T-cell leukemia/lymphoma in mice. 6 Likewise, TEL-JAK2 retroviral transduction of bone marrow cells followed by adoptive transfer into irradiated mice induced a fatal mixed myeloproliferative and T-cell lymphoproliferative disorder. 7 Unexpectedly, although both the TEL-JAK2 and PCM1-JAK2 fusions have been observed in human B-cell leukemia/lymphoma, none of the TEL-JAK2 mouse models developed B-cell malignancies.
To investigate whether the rapidly arising T-cell lymphoma in EmSRa-TEL-JAK2 mice 6 may have obscured the oncogenic activity of TEL-JAK2 in the B-cell lineage, we bred EmSRa-TEL-JAK2 transgenic mice with Cd3e-deficient mice, which do not express the CD3e protein, an essential signaling component of the T-cell receptor (TCR) and pre-TCR complexes, and thus present a complete block in T-cell development at the DN3 doublenegative stage (CD4ÀCD8ÀCD25 þ CD44À). 8 Mice issued from this cross were backcrossed to Cd3e -/-mice, to generate a cohort of 23 Cd3e -/-and 15 Cd3e þ /-animals carrying the EmSRa-TEL-JAK2 transgene. In contrast to EmSRa-TEL-JAK2/ Cd3e þ /-mice, which rapidly succumbed to leukemia/lymphoma (median survival time of 10 weeks), EmSRa-TEL-JAK2/Cd3e -/-mice remained disease-free for a significantly longer period of time (median survival time of 30 weeks) (Figure 1a ). EmSRa-TEL-JAK2/Cd3e þ /-mice showed typical features of disseminated T-cell leukemia, including thymic enlargement, splenomegaly, lymphadenopathy and often nonlymphoid organ invasion, a clinical picture identical to that observed in the original EmSRa-TEL-JAK2 mice. 6 The majority of EmSRa-TEL-JAK2/Cd3e -/-mice (78%; 18 out of 23) also developed external signs of hematological malignancy and invasion of nonlymphoid organs, such as liver and lungs. Macroscopic examination allowed us to divide diseased EmSRa-TEL-JAK2/Cd3e
-/-mice in two subgroups: 12 mice showed a predominant thymic enlargement accompanied by relatively mild splenomegaly, while six mice showed severe splenomegaly accompanied by relatively little or no thymic involvement. Using cell surface immunostaining, we observed that among the 12 cases showing predominant thymic involvement, two tumors (cases #35 and #68) expressed the B220 marker, but were negative for Thy1.2 staining, indicating that these mice developed a thymic B-cell lymphoma (Figure 1c) . The other thymic lymphomas were Thy1.2 þ B220 -. Within the group of six mice presenting mainly splenomegaly, four were analyzed by flow cytometry. These lymphomas (cases #27, #48, #1050, and #1066) were Thy1.2 -B220 þ , indicating the development of a B-cell lineage malignancy (Figure 1d ). These results demonstrate that in the absence of CD3e, EmSRa-TEL-JAK2 transgenic mice develop either T or B hematological disease and that B-cell lymphoma develops after longer latency (median survival time of 50 weeks) than T-cell disease (median survival time of 23 weeks) (Figure 1b) .
To characterize further the B-cell lymphomas arising in EmSRa-TEL-JAK2/Cd3e
-/-mice, we used antibodies specific for markers expressed at different stages of B-cell development, including B220, CD19, CD43, CD24, CD25, IgM and IgD. Expression of the CD43 and CD25 pro-B/pre-B cell markers was infrequent in most cases analyzed, while surface IgM (sIgM) was expressed in all cases and in the majority of tumor cells (Table 1 ; Figure 2 ). In contrast, the surface IgD (sIgD) mature B-cell marker was detected in a low percentage of lymphoma cells and at low levels. The CD24 marker was expressed at high levels in all cases (Figure 2) . These results indicate that the phenotype of TEL-JAK2-induced B-cell lymphomas parallels that of 'immature' or 'transitional' B-cells, which are characterized by the expression of high levels of sIgM and CD24 and no or little sIgD. Interestingly, the combination of the EmSRa-TEL-JAK2 transgene with Rag2 deficiency did not result in B-cell lymphoma, although these animals developed T-cell lymphoma at a rate similar to EmSRa-TEL-JAK2/CD3e
-/-mice (data not shown). Rag2 deficiency also results in a block at the DN3 stage of T-cell development but, in addition, results in a block in B-cell development at the pro-B stage. This observation suggests that the target cells for B-cell lymphoma in EmSRa-TEL-JAK2/Cd3e -/-mice showing splenic B-cell lymphoma (cases #48 and #1066). Wild-type splenocytes (WT spleen) are shown as control. Single-cell suspensions were prepared from lymphoid organs and stained with fluorescein isothiocyanate (FITC)-labeled Thy1.2 and R-phycoerythrin (PE)-labeled B220 antibodies (BD Pharmingen, San Diego, CA, USA), as previously described. Table 1 Macroscopic analysis and cell surface phenotype of EmSRa-TEL-JAK2/Cd3e
-/-B-cell lymphomas #27  50  10  790  50  99   c   ND  98  6  99  ND  7  #35  30  830  170  60  99  83  96  21  99  ND  18  #48  66  260  930  380  90  90  88  28  84  20  59  #68  18  180  60  110  86  ND  ND  ND  ND  2  ND  #1050  52  30  400  100  79  ND  57  6  79  ND  7  #1066  27  10  420  80  82  79  64  9  82  68 
Figure 2
EmSRa-TEL-JAK2/Cd3e -/-B-cell lymphomas display an immature B-cell phenotype. Five representative cases (#27, #35, #48, #1050 and #1066) of EmSRa-TEL-JAK2/Cd3e
-/-B-cell lymphoma were immunostained with different B-cell surface markers. A wild-type (WT) spleen is shown as control. Single-cell suspensions were prepared from lymphoid organs and stained with fluorochrome-labeled antibodies, as described previously.
6 FITC-, PE-, or PE-cyanine 5 (PE-Cy5)-conjugated antibodies specific for B220, CD19, CD24, CD25, CD43, IgM and IgD (BD Pharmingen, San Diego, CA, USA) were used. ments (Figure 3 ), indicating that these tumors correspond to clonal malignancies. This together with the variable latency of individual tumor onset indicates that the acquisition of secondary oncogenic events are involved in disease progression.
The mouse model described herein demonstrates that the TEL-JAK2 fusion protein can transform B-cells in vivo, although it does so less efficiently than in the T-cell lineage, even in the context of CD3e deficiency (Figure 1b) . Although the B-and T-cell lymphoma arising in EmSRa-TEL-JAK2/Cd3e -/-mice express the TEL-JAK2 protein at similar levels (data not shown), this differential activity of TEL-JAK2 in the B-and T-cell lineages could reflect differences either in the size of the respective B-and T-cell populations targeted by TEL-JAK2, in expression of the oncoprotein in these target cells, or in a difference in number and/or frequency of appearance of cooperating oncogenic mutations. To our knowledge, the EmSRa-TEL-JAK2/ Cd3e -/-mice is the only mouse model for TEL-JAK2-induced B-cell malignancy. These mice will help to unravel the molecular mechanisms underlying TEL-JAK2-induced B-and T-cell transformation and to test in vivo therapeutic agents specifically targeting JAK2 signaling.
Figure 3
EmSRa-TEL-JAK2/Cd3e -/-B-cell lymphomas present oligoclonal immunoglobulin heavy chain gene rearrangements. Samples analyzed: an EmSRa-TEL-JAK2 thymic T-cell lymphoma (#324 thy), wild-type splenocytes (WT spl), an EmSRa-TEL-JAK2/ Cd3e -/-thymic T-cell lymphoma (#58 thy), and 5 EmSRa-TEL-JAK2/ Cd3e -/-B-cell lymphomas (#27 spl, #35 thy, #48 spl, #48 LN, #1050 spl) occurring in the thymus (thy), spleen (spl), or lymph nodes (LN). GL indicates the nonrearranged germline band and asterisks represent clonal rearrangements. Southern blot analysis was performed as previously described 6 using EcoRI-digested genomic DNA. The probe was a HindIII/XbaI 900 bp fragment encompassing the JH4 region of the murine Igh locus (kindly provided by Dr M Goodhardt, Institut Pasteur, Paris).
